Biotin methyl ester is a synthetic derivative of biotin, a water-soluble B vitamin. It is often used in research as a more readily soluble and cell-permeable form of biotin. Biotin methyl ester is synthesized through the reaction of biotin with methanol in the presence of a catalyst. The esterification process increases the lipophilicity of biotin, making it more easily absorbed by cells. Studies have shown that biotin methyl ester can stimulate cell growth and proliferation, particularly in cells that are dependent on biotin for their growth. Its importance lies in its potential as a therapeutic agent for various conditions related to biotin deficiency, such as hair loss, skin disorders, and neurological disorders. Research on biotin methyl ester is focused on understanding its mechanisms of action, its potential applications in various disease models, and its safety profile.'
| ID Source | ID |
|---|---|
| PubMed CID | 83871 |
| CHEMBL ID | 1395982 |
| SCHEMBL ID | 132274 |
| MeSH ID | M0367632 |
| Synonym |
|---|
| 608-16-2 |
| biotin methyl ester |
| NCGC00142566-01 |
| methyl 5-[(3as,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoate |
| methyl 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate |
| 1h-thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, methyl ester, (3aalpha,4beta,6aalpha)-(+-)- |
| unii-h3s7e3p0h6 |
| h3s7e3p0h6 , |
| biotin, methyl ester |
| d-biotin methyl ester |
| 1h-thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, methyl ester, (3as-(3a.alpha.,4.beta.,6a.alpha.))- |
| 1h-thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, methyl ester, (3as,4s,6ar)- |
| (+)-biotin methyl ester |
| d-(+)-biotin methyl ester |
| SCHEMBL132274 |
| methyl 5-((3as,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)pentanoate |
| BHEWJAXNLVWPSC-NRPADANISA-N |
| AKOS024282763 |
| CHEMBL1395982 |
| GS-5676 |
| methyl 5-[(3as,4s,6ar)-2-oxo-hexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoate |
| methyl 5-[(3as,4s,6ar)-2-oxo-hexahydrothieno[3,4-d]imidazolidin-4-yl]pentanoate |
| E75764 |
| mfcd27578197 |
| methyl 5-(2-hydroxy-3a,4,6,6a-tetrahydro-1h-thieno[3,4-d]imidazol-6-yl)pentanoate |
| DTXSID90976003 |
| Q27279608 |
| biotinmethylester |
| LCZC2364 |
| CS-0160775 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.0251 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1312182 | Binding affinity to FLAG-tagged human A3G expressed in human 293T cells at 13 uM incubated for 16 hrs by streptavidin agarose based immunoblot analysis | 2016 | Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18 | Zinc-mediated binding of a low-molecular-weight stabilizer of the host anti-viral factor apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G. |
| AID1267729 | Antiviral activity against HIV-1 NL4-3 infected in human M8166 cells assessed as inhibition of viral replication at 20 uM after 5 days by p24 ELISA | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (14.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||